All In Biotech

Drug Trial Radar · NCT04277637

Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies

Last checked: Nov 20, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

437

Actual

Start

Mar 24, 2020

Primary completion

May 31, 2027

Study completion May 31, 2027

Sponsor

Lead sponsor
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Feb 20, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety, tolerability; and to define the maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D); and to evaluate the safety and tolerability of the ramp-up dosing schedule and at the RP2D of BGB-11417 monotherapy, and when given in combination with zanubrutinib and obinutuzumab.

Conditions

  • Mature B-Cell Malignancies

Interventions

  • SonrotoclaxDrug

    Film-coated tablets administered once daily at a dose as specified in the treatment arm

  • ZanubrutinibDrug

    320 mg daily administered as two 80-mg capsules twice a day (160 mg twice a day) or as four 80-mg capsules once a day (320 mg once a day)

  • ObinutuzumabDrug

    Given as an intravenous infusion administered per label.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 30 days after the last dose of study drug, an average of 18 months
  2. Number of Participants Experiencing Serious Adverse Events (SAEs)Time frame: Up to 30 days after the last dose of study drug, an average of 18 months
  3. Number of Participants Experiencing Adverse Events (AEs) leading to discontinuation of SonrotoclaxTime frame: Up to 30 days after the last dose of study drug, an average of 18 months
  4. Part 1, Part 3: Maximum Tolerated Dose (MTD) of SonrotoclaxTime frame: Up to approximately 2 months
  5. Part 1, Part 3, Part 5: RP2D of SonrotoclaxTime frame: Day 1 to last dose of study drug, an average of 18 months
  6. Part 1, Part 3, Part 5: Number of participants experiencing tumor lysis syndrome (TLS) relevant eventsTime frame: Up to 30 days after the last dose of study drug, an average of 18 months
  7. Part 1, Part 3, Part 5: Number of Participants Experiencing Dose-Limiting Toxicities (DLTsTime frame: Up to approximately 2 months

Locations

43 sites in 7 countries. Site status is shown where the registry gives one.

  • UCLA Hematologyoncology

    Los Angeles, California

  • Northwestern University

    Chicago, Illinois

  • University of Kansas Medical Center Research Institute

    Kansas City, Kansas

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • John Theurer Cancer Center Hackensack University Medical Center

    Hackensack, New Jersey

  • Columbia University Medical Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center Mskcc

    New York, New York

  • The James Cancer Hospital and Solove Research Institute At Ohio State University

    Columbus, Ohio

  • Upmc Hillman Cancer Center(Univ of Pittsburgh)

    Pittsburgh, Pennsylvania

  • Md Anderson Cancer Center

    Houston, Texas

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

  • Concord Repatriation General Hospital

    Concord, New South Wales, Australia

  • Orange Health Service (Central West Cancer Care Centre)

    Orange, New South Wales, Australia

  • Pindara Private Hospital

    Benowa, Queensland, Australia

  • John Flynn Private Hospital

    Tugun, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Flinders Medical Centre

    Bedford PK, South Australia, Australia

  • Box Hill Hospital

    Box Hill, Victoria, Australia

  • Monash Health

    Clayton, Victoria, Australia

  • St Vincents Hospital Melbourne

    Fitzroy, Victoria, Australia

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • Linear Clinical Research

    Nedlands, Western Australia, Australia

  • Universitatsklinikum Carl Gustav Carus An Der Technischen Universitat Dresden

    Dresden, Germany

  • Ospedale San Raffaele

    Milan, Italy

  • Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

    Milan, Italy

  • Ospedale Santa Maria Della Misericordia

    Perugia, Italy

  • Azienda Unita Sanitaria Locale Di Ravenna

    Ravenna, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli

    Roma, Italy

  • Centroricerche Cliniche Di Verona Srl

    Verona, Italy

  • North Shore Hospital

    Auckland, New Zealand

  • Auckland City Hospital

    Auckland, New Zealand

  • Wellington Regional Hospital (Ccdhb)

    Wellington, New Zealand

  • Vall D Hebron Institute of Oncology Vhio

    Barcelona, Spain

  • Hospital Clinic de Barcelona

    Barcelona, Spain

  • Hospital de La Santa Creu I Sant Pau

    Barcelona, Spain

  • Ico H Duran I Reynals

    Barcelona, Spain

  • Start Madrid Fundacion Jimenez Diaz

    Madrid, Spain

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.